News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Theranostics Health Announces Issuance Of U.S. Patent 8,628,931 B2: mTOR Pathway Theranostic

2/26/2014 10:12:33 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Rockville, MD – February 26, 2014: Theranostics Health Inc. announced today that the U.S. Patent and Trademark Office issued Patent Number 8,628,931 B2 entitled: “mTOR Pathway Theranostic” on January 14, 2014. This patent is exclusively licensed to Theranostics Health from George Mason Intellectual Properties. The invention relates to methods for predicting a subject’s response to chemotherapeutic agents and the patient’s prognosis by measuring the phosphorylation state of at least one member of the mTOR (Mammalian Target of Rapamycin) pathway, or by measuring the activity of members of interconnected signaling pathways, like the Akt or IRS (Insulin Receptor Substrate) pathways. Also claimed is a method for treating a cancer in a subject who exhibits elevated phosphorylation states of key proteins in these pathways, by the administration of one or more inhibitors of mTOR or members of its interconnected pathways. Currently, there are several U. S. Food and Drug Administration approved targeted therapies that inhibit mTOR signaling, which has been identified as a key signal transduction pathway that is active in a sub-population of ER-positive breast cancer patients who fail to respond to anti-hormone or anti-aromatase therapies or who develop resistance to therapy. Anti-mTOR therapy is now part of the Standards of Care for this sub-population of breast cancer patients. Theranostics Health’s TheraLink™ HER Family Assay is the first commercial assay that measures mTOR activation and the activation of key associated signaling pathways.

“Theranostics Health believes that the allowance of this patent enhances the Company’s position in the proteomic-based diagnostic and therapeutic markets. This issuance on mTOR signaling provides an additional layer of intellectual property that supports the Company’s licensed issued patent for guiding combinations of therapies based on the signaling architecture in each individual tumor (USPTO# 8,168,568 B1)”, stated Glenn Hoke, President and CEO of Theranostics Health. In addition to this patent, Theranostics Health is the beneficiary of multiple pending applications encompassing a wide-range of oncology indications through its exclusive license with the George Mason Research Foundation.

About Theranostics Health Inc.

Theranostics Health, a privately-held biotechnology company, develops technologies to measure the activation status of key signaling pathways that are instrumental in the development and progression of cancers and for which there are therapies without guiding tests. While the Company has historically focused on providing services to pharmaceutical and biotechnology drug development companies, Theranostics Health is now offering oncologists proteomic-based molecular diagnostic tests through its TheraLink™ HER Family Assay and has a number of additional tests in development.

Contact Ron Hencin, Ph.D. Vice President of Business Development 301-251-4443, Extension 119

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus